Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 305.879
Filtrar
1.
Rev. enferm. UERJ ; 29: e56924, jan.-dez. 2021.
Artículo en Inglés, Portugués | LILACS | ID: biblio-1224444

RESUMEN

Objetivo: descrever a incidência de complicações em feridas operatórias de mastectomia e identificar fatores associados. Método: estudo retrospectivo desenvolvido em uma coorte hospitalar de 545 mulheres mastectomizadas por câncer de mama no ano 2018 em um centro de assistência de alta complexidade em oncologia da cidade do Rio de Janeiro, Brasil, após aprovação por Comitê de Ética em Pesquisa. Os dados foram coletados a partir dos prontuários, permitindo cálculos da taxa de incidência e da razão da taxa de incidência para cada complicação. Resultados: a complicação que apresentou maior taxa de incidência foi o sangramento (57,14/100 mastectomias-dia), tendo como fatores associados a raça/cor da pele não branca (Razão da Taxa de Incidência: 3,11) e a diabetes mellitus (Razão da Taxa de Incidência: 0,48). Conclusão: os fatores associados ao sangramento da ferida operatória apontam para a necessidade de novas práticas no cuidado ao pós-operatório de mulheres mastectomizadas.


Objective: to describe the incidence of complications in mastectomy surgical wounds and to identify associated factors. Method: this retrospective study was conducted in a hospital cohort of 545 women mastectomized for breast cancer in 2018 at a high-complexity cancer care center Rio de Janeiro City, Brazil, after approval by the research ethics committee. Data were collected from medical records, allowing incidence rate and incidence rate ratio to be calculated for each complication. Results: the complication with the highest incidence rate was bleeding (57.14/100 mastectomies-day), associated factors being non-white race/skin color (incidence rate ratio 3.11) and diabetes mellitus (incidence rate ratio 0.48). Conclusion: the factors associated with bleeding from the surgical wound point to the need for new practices in post-operative care for women with mastectomies.


Objetivo: describir la incidencia de complicaciones en heridas quirúrgicas de mastectomía e identificar factores asociados. Método: estudio retrospectivo desarrollado en una cohorte hospitalaria de 545 mujeres mastectomizadas por cáncer de mama en 2018 en un centro de atención de alta complejidad en oncología de la ciudad de Río de Janeiro, Brasil, previa aprobación del Comité de Ética en Investigación. Los datos se obtuvieron de las historias clínicas, lo que permitió calcular la tasa de incidencia y el cociente de la tasa de incidencia para cada complicación. Resultados: la complicación que presentó mayor tasa de incidencia fue el sangrado (57,14 / 100 mastectomías-día), con factores asociados a la raza / color de piel no blanca (índice de tasa de incidencia: 3,11) y diabetes mellitus (índice de tasa de incidencia: 0,48). Conclusión: los factores asociados al sangrado de la herida quirúrgica apuntan a la necesidad de nuevas prácticas en el cuidado al postoperatorio de las mujeres con mastectomía.


Asunto(s)
Humanos , Femenino , Adulto , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Adulto Joven , Complicaciones Posoperatorias/epidemiología , Herida Quirúrgica/complicaciones , Mastectomía/efectos adversos , Brasil/epidemiología , Neoplasias de la Mama/cirugía , Incidencia , Estudios Retrospectivos , Factores de Riesgo , Hemorragia Posoperatoria/epidemiología
2.
World J Surg Oncol ; 19(1): 294, 2021 Oct 02.
Artículo en Inglés | MEDLINE | ID: mdl-34600547

RESUMEN

BACKGROUND: Breast cancer (BC) has a high incidence and mortality rate in females. Its conventional clinical characteristics are far from accurate for the prediction of individual outcomes. Therefore, we aimed to develop a novel signature to predict the survival of patients with BC. METHODS: We analyzed the data of a training cohort from the Cancer Genome Atlas (TCGA) database and a validation cohort from the Gene Expression Omnibus (GEO) database. After the applications of Gene Set Enrichment Analysis (GSEA) and Cox regression analyses, a glycolysis-related signature for predicting the survival of patients with BC was developed; the signature contained AK3, CACNA1H, IL13RA1, NUP43, PGK1, and SDC1. Furthermore, on the basis of expression levels of the six-gene signature, we constructed a risk score formula to classify the patients into high- and low-risk groups. The receiver operating characteristic (ROC) curve and the Kaplan-Meier curve were used to assess the predicted capacity of the model. Later, a nomogram was developed to predict the outcomes of patients with risk score and clinical features over a period of 1, 3, and 5 years. We further used Human Protein Atlas (HPA) database to validate the expressions of the six biomarkers in tumor and sample tissues, which were taken as control. RESULTS: We constructed a six-gene signature to predict the outcomes of patients with BC. The patients in the high-risk group showed poor prognosis than those in the low-risk group. The area under the curve (AUC) values were 0.719 and 0.702, showing that the prediction performance of the signature is acceptable. Additionally, Cox regression analysis revealed that these biomarkers could independently predict the prognosis of BC patients with BC without being affected by clinical factors. The expression levels of all six biomarkers in BC tissues were higher than that in normal tissues; however, AK3 was an exception. CONCLUSION: We developed a six-gene signature to predict the prognosis of patients with BC. Our signature has been proved to have the ability to make an accurate prediction and might be useful in expanding the hypothesis in clinical research.


Asunto(s)
Neoplasias de la Mama , Biomarcadores de Tumor/genética , Biomarcadores de Tumor/metabolismo , Neoplasias de la Mama/genética , Femenino , Regulación Neoplásica de la Expresión Génica , Glucólisis , Humanos , Estimación de Kaplan-Meier , Pronóstico
3.
Anticancer Res ; 41(10): 4715-4718, 2021 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-34593419

RESUMEN

BACKGROUND/AIM: Primary osteosarcoma of the breast is an exceedingly-rare malignant tumor that shares histological characteristics with osteosarcoma of the bone. Since effective therapies have not yet been established, standard therapy for osteosarcoma of the bone was examined in the present study for efficacy against primary osteosarcoma of the breast in a patient-derived orthotopic xenograft (PDOX) nude-mouse model. MATERIALS AND METHODS: The PDOX mouse models were established by surgical implantation of the primary osteosarcoma of the breast specimen into the mammary gland of nude mice. Mice with tumors were randomized into four groups, each n=4: control group; cisplatinum (CDDP)-treatment group; doxorubicin (DOX)-treatment group; and CDDP/DOX-combination-treatment group. Mice were treated for twenty-one days, three weeks after implantation. Tumor size and body weight were measured during three weeks of treatment. RESULTS: Significant tumor growth inhibition was observed, compared to the control, in the CDDP-treatment group, the DOX-treatment group, and the combination-treatment-group. Only the combination treatment regressed the tumor. CONCLUSION: CDDP and DOX which are standard first-line therapies for osteosarcoma, may be clinically effective against primary osteosarcoma of the breast, and in particular, their combination.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Cisplatino/uso terapéutico , Doxorrubicina/uso terapéutico , Osteosarcoma/tratamiento farmacológico , Animales , Neoplasias de la Mama/patología , Modelos Animales de Enfermedad , Femenino , Humanos , Ratones , Ratones Desnudos , Osteosarcoma/patología , Carga Tumoral/efectos de los fármacos , Ensayos Antitumor por Modelo de Xenoinjerto
4.
J Nepal Health Res Counc ; 19(2): 246-251, 2021 Sep 06.
Artículo en Inglés | MEDLINE | ID: mdl-34601511

RESUMEN

BACKGROUND: Destructive ocular surgeries are performed for many conditions ranging from trauma to tumours, where the eyes cannot be salvaged. The objective of our research was to study the profile of destructive ocular surgery and their indications. METHODS: This retrospective study reviewed all patients who underwent evisceration, enucleation, and exenteration at B.P. Koirala Institute of Health Sciences, a tertiary eye hospital in Eastern Nepal, between January 2008 and December 2019. Medical records on patient demographics, type of surgery performed, and an indication of surgery during the study period were reviewed. RESULTS: One hundred thirty-four patients underwent destructive ocular surgeries. The median age of patients undergoing surgery was 14.5 (3-50) years. Children aged ten years or less accounted for 46.3% of the total patients. Fifty-two percent were male. The left eye was affected in more than half of the cases (56.7%). Enucleation was the most performed destructive ocular surgery (76 cases, 56.7%). Intraocular and ocular adnexal malignancy was the most common overall indication (62 cases, 46.3%). Ocular infection (19 cases, 41.3%) and trauma (15 cases, 32.6%) were the most common indication of evisceration. Retinoblastoma accounted for most cases of enucleation (43 cases, 56.6%). Malignancy was the only indication of exenteration (12 cases, 100%). CONCLUSIONS: Enucleation was the most common destructive ocular surgery. Malignancy accounted for most of the cases of destructive eye surgery, followed by ocular infection. Ocular infection and trauma were the most common indication of evisceration, whereas retinoblastoma and eyelid malignancy were responsible for most of the cases of enucleation and exenteration, respectively.


Asunto(s)
Neoplasias de la Mama , Medicina , Adolescente , Adulto , Niño , Humanos , Masculino , Persona de Mediana Edad , Nepal/epidemiología , Estudios Retrospectivos , Centros de Atención Terciaria , Adulto Joven
5.
J Nepal Health Res Counc ; 19(2): 331-336, 2021 Sep 06.
Artículo en Inglés | MEDLINE | ID: mdl-34601526

RESUMEN

BACKGROUND: Breast cancer in women is a major health burden. In Nepal, most common cancer in female is breast cancer. Knowledge plays an important role in improvement of health seeking behavior. Knowledge may positively affect attitude and practice. So, this study aims to assess the knowledge and attitude regarding breast cancer among the adolescents. METHODS: A cross-sectional study was done among students of 23 randomly selected highher secondary schools of Bhaktapur district. Total 990 participant were assessed with questionnaire regarding knowledge and attitude towards breast cancer. RESULTS: Out of total 400 participants, 89.6% of male and 88.5% of female respondents had poor knowledge regarding breast cancer. 63.2% of the female and 50.9% of the male respondents had good attitude towards breast cancer. Religion, education of parents and ethnicity of respondents showed positive association with respondent's knowledge of breast cancer. Gender, education and ethnicity of respondents showed positive association with respondent's attitude of breast cancer. CONCLUSIONS: Majority of the respondents had poor knowledge and half of respondents had good attitude towards breast cancer. Therefore, educational programs and awareness campaigns that target adolescents to improve their knowledge and attitude regarding breast cancer must be encouraged.


Asunto(s)
Neoplasias de la Mama , Adolescente , Estudios Transversales , Femenino , Humanos , Conocimiento , Masculino , Nepal , Percepción
6.
J Coll Physicians Surg Pak ; 31(10): 1234-1236, 2021 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-34601849

RESUMEN

We present a case of a 49-year Turkish woman who had synchronous renal leiomyoma and breast cancer. The patient was evaluated for a suspicious breast mass; and renal mass was detected incidentally by contrast-enhanced computed tomography (CT). Diagnostic tru-cut biopsy was performed for both masses. Breast mass biopsy was reported as invasive ductal carcinoma (IDC) while renal biopsy was described as benign mesenchymal tumour. According to the biopsy results, the renal mass was followed for six months. For breast cancer, segmental mastectomy and concomitant sentinel lymph node biopsy was performed. Histologically, the tumour was reported as IDC and low-grade cribriform ductal carcinoma in situ (less than 1%). Six months later, renal mass was excised by laparoscopic approach. Histopathological examination was consistent with renal leiomyoma. For both tumours, no recurrence within one year was found on follow-up. Key Words: Renal leiomyoma, Breast cancer, Laparoscopy.


Asunto(s)
Neoplasias de la Mama , Leiomioma , Neoplasias de la Mama/cirugía , Femenino , Humanos , Leiomioma/diagnóstico por imagen , Leiomioma/cirugía , Mastectomía , Recurrencia Local de Neoplasia , Biopsia del Ganglio Linfático Centinela
7.
Mymensingh Med J ; 30(4): 1124-1130, 2021 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-34605486

RESUMEN

Female breast cancer can be diagnosed easily; but due to inappropriate health care utilization, health-seeking is lag behind. The objectives of the study were to find out the pattern of utilization of health care during breast cancer diagnosis and treatment and their health seeking time. We conducted this cross sectional study for one year; from July 2017 to June 2018 among 200 newly diagnose patients with breast cancer whose were selected randomly from National Institute of Cancer Research and Hospital, Dhaka, Bangladesh from the listed patients who attended at the outpatient department of chemotherapy day care center for treatment. Delay in reporting, wrong reporting, double reporting, delay in hospital admission, long queue for administrative work and delay to reach cancer specialist play a role in utilization of health care. Results showed that health care service delivery and utilization was found to be significant by (p<0.05) associated with the provider delay (p=0.010), total delay (p=0.017), delay to consult with cancer specialist (p<0.0001). By logistic regression it analyzed that utilization of health care there had 2 times more likely to cause provider delay (OR=2.5; 95% CI 1.087-5.762) p=0.03. Utilization of health care influenced stage of cancer with delay help seeking and diagnostic institution also. As low middle income country, like Bangladesh, delays in seeking consultation, late presentation and the availability of breast cancer management for all patients, represent major challenges.


Asunto(s)
Neoplasias de la Mama , Bangladesh/epidemiología , Neoplasias de la Mama/diagnóstico , Neoplasias de la Mama/terapia , Estudios Transversales , Diagnóstico Tardío , Femenino , Humanos , Aceptación de la Atención de Salud , Derivación y Consulta
8.
BMJ Case Rep ; 14(10)2021 Oct 05.
Artículo en Inglés | MEDLINE | ID: mdl-34610954

RESUMEN

Synchronous primary malignancies are most frequently seen with cancers of the stomach and oesophagus, mainly attributed to the similar genetic mutations. Most of these multiple malignancies turn out to be metastatic or metachronous lesions. Multiple synchronous malignancies are rarer than metachronous ones. Primary synchronous breast and renal cancer is even rare. These patients require extensive workup to exclude all possible metastases. The nature of the primary tumours must also be confirmed, prior to any treatment strategy. We report the case of a healthy, middle-aged woman who initially presented with a lesion suspicious for breast carcinoma, and further workup revealed the presence of an asymptomatic, synchronous primary renal cell cancer, which is a very rare presentation.


Asunto(s)
Neoplasias de la Mama , Carcinoma de Células Renales , Neoplasias Renales , Neoplasias Primarias Múltiples , Neoplasias de la Mama/diagnóstico , Carcinoma de Células Renales/diagnóstico por imagen , Femenino , Humanos , Riñón , Neoplasias Renales/diagnóstico por imagen , Persona de Mediana Edad , Neoplasias Primarias Múltiples/diagnóstico
9.
Rev Bras Enferm ; 75(1): e20210118, 2021.
Artículo en Inglés, Portugués | MEDLINE | ID: mdl-34614087

RESUMEN

OBJECTIVE: To estimate the incidence and degree of acute radiodermatitis at the end and after the end of treatment in women with breast cancer undergoing hypofractionated radiotherapy. METHODS: Observational, prospective, and longitudinal study, conducted between March 2019 and January 2020, in a radiotherapy outpatient clinic. RESULTS: Thirty-two women participated in the study, among whom, in the last session of hypofractionated radiotherapy, 15 (46.9%) had radiodermatitis, erythema in 13 (40.6%), and wet peeling in 2 (6.3%). In the post-treatment evaluation, 27 (84.4%) had radiodermatitis, erythema in 17 (53.1%), dry peeling in 8 (25%), and wet peeling in 2 (6.3%). CONCLUSION: The general incidence of radiodermatitis after hypofractionated radiotherapy in women with breast cancer was 37.5%, erythema, 12.5%, and dry peeling, 25%. The development of care protocols for the management of radiodermatitis after treatment is of paramount importance.


Asunto(s)
Neoplasias de la Mama , Radiodermatitis , Neoplasias de la Mama/complicaciones , Neoplasias de la Mama/radioterapia , Femenino , Humanos , Incidencia , Estudios Longitudinales , Estudios Prospectivos , Radiodermatitis/epidemiología , Radiodermatitis/etiología
10.
Prague Med Rep ; 122(3): 212-215, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34606433

RESUMEN

A fatal case of 67-year-old female with metastatic breast cancer on chemotherapy complicated with febrile neutropenia, colitis and sepsis due to Clostridium septicum is presented. Important clinical symptoms, laboratory and radiology findings together with therapy and outcome of neuropenic colitis are also discussed.


Asunto(s)
Bacteriemia , Neoplasias de la Mama , Infecciones por Clostridium , Clostridium septicum , Colitis , Anciano , Bacteriemia/diagnóstico , Neoplasias de la Mama/complicaciones , Infecciones por Clostridium/complicaciones , Infecciones por Clostridium/diagnóstico , Colitis/diagnóstico , Colitis/etiología , Femenino , Humanos
11.
Anticancer Res ; 41(10): 5007-5014, 2021 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-34593449

RESUMEN

BACKGROUND/AIM: In our previous study, first-line eribulin (ERI) showed 25 weeks of progression-free survival (PFS). This study investigated the efficacy and safety of ERI re-administration in metastatic breast cancer (MBC) patients. PATIENTS AND METHODS: HER2-negative MBC patients who had never received chemotherapy for MBC received first-line ERI for 18 weeks if they did not have disease progression, and then one cycle of S-1 before ERI re-administration. RESULTS: Twelve patients received ERI re-administration. The PFS of re-administered ERI was 13 weeks. Total duration of ERI use was 30 weeks. The incidence and severity of adverse events were consistent with previous reports. CONCLUSION: In the first-line setting, the total PFS of eribulin was extended by S-1 administration before disease progression, compared with that of our previous report.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Biomarcadores de Tumor/metabolismo , Neoplasias de la Mama/tratamiento farmacológico , Recurrencia Local de Neoplasia/tratamiento farmacológico , Receptor ErbB-2/metabolismo , Adulto , Anciano , Neoplasias de la Mama/metabolismo , Neoplasias de la Mama/patología , Femenino , Fluorouracilo/administración & dosificación , Estudios de Seguimiento , Furanos/administración & dosificación , Humanos , Cetonas/administración & dosificación , Persona de Mediana Edad , Recurrencia Local de Neoplasia/metabolismo , Recurrencia Local de Neoplasia/patología , Pronóstico , Retratamiento , Tasa de Supervivencia
12.
Anticancer Res ; 41(10): 5045-5052, 2021 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-34593453

RESUMEN

BACKGROUND/AIM: To examine the association between sense of coherence (SOC) and health-related quality of life (HRQoL) in early breast cancer patients. PATIENTS AND METHODS: The study population included 406 disease-free breast cancer survivors who participated in 3-year and 5-year follow-ups of a randomized exercise intervention. SOC was assessed using the short version of the Orientation to life questionnaire (SOC-13) in the 3-year follow-up. HRQoL was self-reported using the EORTC QLQC30 questionnaire in both 3-year and 5-year follow-ups. The association between SOC and HRQoL was analyzed using the Spearman's rank correlation coefficient. RESULTS: SOC had a strong positive correlation with global HRQoL in both 3-year (rs=0.57, p<0.01) and 5-year (rs=0.51, p<0.01) follow-ups. CONCLUSION: This study provides evidence of SOC's predictive value for HRQoL in early breast cancer patients. SOC might be used for identifying patients who will profit most from psychosocial support and intervention during the rehabilitation period.


Asunto(s)
Adaptación Psicológica , Neoplasias de la Mama/patología , Neoplasias de la Mama/psicología , Supervivientes de Cáncer/psicología , Calidad de Vida , Sentido de Coherencia/fisiología , Adulto , Anciano , Femenino , Estudios de Seguimiento , Humanos , Persona de Mediana Edad , Pronóstico , Estudios Prospectivos , Encuestas y Cuestionarios , Tasa de Supervivencia
15.
Clin Ter ; 172(5): 453-460, 2021 Sep 29.
Artículo en Inglés | MEDLINE | ID: mdl-34625779

RESUMEN

Background: This study aimed to correlate dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) parameters with prognostic factors in breast cancer. Methods: A retrospective analysis was performed in 45 patients who had breast DCE-MRI and were diagnosed with invasive ductal breast cancer following surgery. The following DCE-MRI parameters were calculated: percentage of initial peak enhancement (Epeak), time to initial peak enhancement (TTP), initial slope increase (IS), early signal enhancement ratio (ESER), and time-signal intensity curve (TIC) types. Correlations between Epeak, TTP, IS, ESER, and prognostic factors were determined using the Mann-Whitney U test and the Kruskal-Wallis test. The Chi-square test and Fisher's exact test were used to investigate the relationship between kinetic curve types and prognostic factors. Results: Epeak and IS were significantly higher in the Ki-67 high-expression group than in the Ki-67 low-expression group (p = 0.031 and p = 0.012, respectively). ESER was significantly correlated with the histological type and Ki-67 expression level (p = 0.014 and p = 0.047, respectively). The TIC types were significantly correlated with the Ki-67 expression level (p = 0.009). Tumors with plateaus and washout curves were more likely to be associated with the Ki-67 high-expression group than tumors with a persistent curve (P = 0.027 and P = 0.038, respectively). TTP had no correlation with any prognostic factors (P > 0.05). Conclusions: This study showed that the DCE-MRI parameters of breast cancer were correlated with the expression of histopathological prognostic factors and might be useful for predicting prognosis.


Asunto(s)
Neoplasias de la Mama , Mama , Neoplasias de la Mama/diagnóstico por imagen , Medios de Contraste , Femenino , Humanos , Imagen por Resonancia Magnética , Estudios Retrospectivos
16.
Ann Palliat Med ; 10(9): 10075-10082, 2021 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-34628927

RESUMEN

OBJECTIVE: In this review, we aimed to discuss the efficacy of immunotherapy of anti-programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) and potential immune mechanism combination with various standard systemic therapies for breast cancer (BC) such as chemotherapy, targeted therapy, endocrine therapy, and radiotherapy. BACKGROUND: Single-drug therapy of antibodies against PD-1 and its ligand, PD-L1, have only presented modest responses in patients with BC, partly due to the deficiency of tumor-infiltrating lymphocytes (TILs) and low mutation burden. Thus, the combinations of PD-1/PD-L1 blockade with other approaches which may increase the immune therapy effect are being studied. Moreover, an understanding of the immune mechanism of PD-1/PD-L1 blockade with other approaches will contribute to better application of clinical therapy. METHODS: We searched the studies that focus on PD-1/PD-L1 therapy with or without other systemic therapy and relative immune mechanisms indicated between 2000 and 2020. CONCLUSIONS: Anti PD-1/L1 blockade combined with therapeutic approaches is safe and effective in BC, in particular for PD-L1 antibody atezolizumab plus nab-paclitaxel by inducing PD-1/L1 expression and the number of cytotoxic T cells. Otherwise, the toxicity also exists during clinical treatment. Future researches should be evaluated to explore the immune mechanism and vast clinical trials need to be conducted for evidential support for combination therapy of BC.


Asunto(s)
Antígeno B7-H1 , Neoplasias de la Mama , Neoplasias de la Mama/tratamiento farmacológico , Terapia Combinada , Femenino , Humanos , Ligandos , Receptor de Muerte Celular Programada 1
17.
Ann Palliat Med ; 10(9): 10124-10129, 2021 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-34628933

RESUMEN

Breast cancer is the most commonly diagnosed malignant tumor and the leading cause of cancer-related death in women worldwide. Previous studies have demonstrated that patients with human epidermal growth factor receptor 2 (HER2)-positive/hormone receptor (HR)-positive metastatic breast cancer can benefit from HER2-targeted therapy. Pyrotinib, an irreversible tyrosine kinase inhibitor (TKI), has been demonstrated to be effective and safe in treating HER2-positive breast cancer patients. Letrozole is an aromatase inhibitor (AI) which has shown better clinical efficacy when combined with HER2 inhibitors in treating patients with HER2-positive and HR-positive breast cancer than has hormonal therapy alone. However, the effect of combination therapy with pyrotinib plus letrozole in HER2-positive/HR-positive metastatic breast cancer patients has not yet been investigated. In this case report, a 57-year-old female patient with HER2-positive/HR-positive breast cancer received modified radical mastectomy and experienced subsequent relapse and metastasis. She was diagnosed with relapsed right breast cancer, a right chest bone mass accompanied by bone destruction, and metastases in the chest wall and both lungs. She was then enrolled in a phase II clinical trial and was treated with pyrotinib plus letrozole, and achieved a durable clinical response. Our case shows that combination therapy with pyrotinib plus letrozole may provide significant clinical benefit for patients with HER2-positive/HR-positive metastatic breast cancer, with tolerable adverse events.


Asunto(s)
Neoplasias de la Mama , Acrilamidas , Aminoquinolinas , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Femenino , Hormonas , Humanos , Letrozol/uso terapéutico , Mastectomía , Persona de Mediana Edad
18.
Nihon Shokakibyo Gakkai Zasshi ; 118(10): 952-958, 2021.
Artículo en Japonés | MEDLINE | ID: mdl-34629345

RESUMEN

A 53-year-old woman visited the hospital of this study complaining of constipation. Colonoscopy revealed a circumferential tumor with severe stenosis, and a computed tomography scan showed neoplastic lesions in the rectum and right breast area. Histology was poorly differentiated adenocarcinoma, requiring differentiation between type 4 and metastatic rectal cancer. Additional immunohistochemical tests were performed and a rectal metastasis of breast cancer diagnosis was made. Hormonal therapy was effective and the tumor volume was significantly reduced. Rectal metastasis of breast cancer is said to be rare. However, in the case of patients diagnosed with breast cancer or with a history of breast cancer, considering the possibility of gastrointestinal metastasis using histopathological examination is important.


Asunto(s)
Adenocarcinoma , Neoplasias de la Mama , Neoplasias del Recto , Neoplasias de la Mama/diagnóstico por imagen , Femenino , Humanos , Persona de Mediana Edad , Neoplasias del Recto/diagnóstico por imagen , Recto , Tomografía Computarizada por Rayos X
19.
Anticancer Res ; 41(10): 5081-5087, 2021 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-34593458

RESUMEN

BACKGROUND: Pharmacological inhibition of osteoclast activity is an essential component of oncological therapy for patients with bone metastases. In rare cases, medication-related osteonecrosis of the jaws (MRONJ) is observed. MRONJ can cause bone defects not inferior to primary or metastatic jaw neoplasms. Oral examination of patients on osteoclast-inhibiting medication aims to identify risk factors at an early stage and to initiate therapy. The current focus on osteoclast-inhibiting drugs in the maxillofacial region is MRONJ. Effects of the substances other than MRONJ are rarely reported. CASE REPORT: The female patient with metastatic breast cancer had developed extensive osteolysis of the mandibular ramus at the time of initial diagnosis. The patient was treated with denosumab. Seven months later, a significant reduction in the mandibular osteolytic zone was recorded. However, known bone metastases from other sites had increased in size during multimodal therapy, and further metastases were recorded. CONCLUSION: Jaw metastasis can shrink under denosumab therapy.


Asunto(s)
Conservadores de la Densidad Ósea/efectos adversos , Neoplasias Óseas/secundario , Neoplasias de la Mama/tratamiento farmacológico , Denosumab/efectos adversos , Neoplasias Mandibulares/patología , Adulto , Neoplasias Óseas/inducido químicamente , Neoplasias de la Mama/patología , Progresión de la Enfermedad , Femenino , Humanos , Neoplasias Mandibulares/inducido químicamente , Pronóstico
20.
Ann Saudi Med ; 41(5): 257-267, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34618610

RESUMEN

BACKGROUND: Breast cancer is the most common malignancy among women in Kuwait, representing 39.8% of all female cancer cases. OBJECTIVES: Report the data of the Kuwait National Mammography Screening Program (KNMSP) for a 5-year period. DESIGN: Prospective data collection. SETTING: Population-based screening. SUBJECTS AND METHODS: We included mammography screens done for Kuwaiti women (age 40 years and older) who attended the KNMSP from 2014 to 2019 to screen for breast cancer. A full-field digital mammography system was used to acquire the mammographic images in craniocaudal and mediolateral oblique projections. Independent double-blind reading of the mammograms was performed by two radiologists. MAIN OUTCOME MEASURE: Early detection of breast cancer. SAMPLE SIZE: 14 773 asymptomatic women met inclusion criteria (mean [SD] age, 51.8 (8.2). RESULTS: Lesions were detected in 551 women (3.7%). These included 233 malignant lesions (233/551, 42.3%), 57 high-risk lesions (10.3%) and 261 benign lesions (47.4%). The participation rate was 7.8% of the target population of women 40-69 years of age. The majority of breast cancer cases were reported in the age group 45-49 years (23.2%). The KNMSP study recall rate for 5 consecutive years was in a range of 11.9-16.5% (mean, 14.3%). The detection rate of ductal/lobular carcinoma in situ and invasive breast cancer were 2.5 and 13.6 per 1000 screened women, respectively. Invasive ductal carcinoma was the most common type. Only 4314 women followed up within 12-15 months of the first mammography for a retention rate of 29.2%. CONCLUSIONS: Screening mammography improves early detection of breast cancer in women older than 40 years but poor participation is a limitation. We are aiming to increase the participation rate to 70% of the population. LIMITATIONS: Lack of participation by women. CONFLICT OF INTEREST: None.


Asunto(s)
Neoplasias de la Mama , Mamografía , Adulto , Neoplasias de la Mama/diagnóstico por imagen , Neoplasias de la Mama/epidemiología , Detección Precoz del Cáncer , Femenino , Humanos , Kuwait/epidemiología , Tamizaje Masivo , Persona de Mediana Edad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...